Revenue growth is accelerating (14% YoY) and gross margins are expanding, but the company remains unprofitable with GAAP and non-GAAP losses. The Q4 guidance midpoint of $31M implies flat sequential revenue. Watch for the trajectory of operating leverage and cash burn in the next quarter, as well as the ramp of new product launches (Colli-Pee Dx, OraQuick Ebola 2.0) into 2027.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $3.33entry
- T+1 · 6d ago +6.91%α +5.59% · $3.56
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
OraSure reported Q3 2026 revenue of $30.9M, up 14% YoY and 1% sequentially, beating the $31.0M consensus. GAAP EPS was -$0.19, slightly worse than the -$0.18 consensus, while non-GAAP EPS was -$0.15. Core business revenue grew 14% YoY, gross margin improved 170 bps to 45.2%, and the company guided Q4 revenue of $30M-$32M, implying full-year growth of ~4.7%.
Key Financial Metrics
Key Facts
- Q3 2026 total net revenue $30.9M, up 14% YoY and 1% sequentially
- GAAP EPS -$0.19 vs consensus -$0.18 (miss by $0.01)
- Non-GAAP EPS -$0.15 vs prior year -$0.13
- Core business revenue (ex-COVID and Risk Assessment) $30.9M, up 14% YoY
- Diagnostics revenue $16.8M, up 16% YoY; Sample Management Solutions $12.5M, up 21% YoY
- GAAP gross margin 45.2%, up 170 bps YoY from 43.5%
- GAAP operating loss improved to $13.0M from $16.1M YoY
- Cash and equivalents $148M as of Sep 30, 2026, down from $199M at Dec 31, 2025
- Q4 2026 revenue guidance $30M-$32M
- Initial orders received for Colli-Pee Dx and OraQuick Ebola 2.0 in Q3
Financial Impact
Revenue beat consensus by $0.1M (0.3%), EPS missed by $0.01 (5.6%); gross margin improved 170 bps; cash burn of $51M YTD
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Diagnostics | $16.8M | +16.0% |
| Sample Management Solutions | $12.5M | +21.0% |
| Other products and services | $771.0K | +74.0% |
| COVID-19 Diagnostics | $22.0K | -75.0% |
| Risk Assessment Testing | $0.00 | Not reported |
Risk Factors
- Continued GAAP and non-GAAP net losses with no near-term profitability timeline
- Cash burn of $51M YTD, cash down to $148M from $199M at year-end 2025
- Revenue guidance for Q4 implies only ~4.7% full-year growth, below the 14% Q3 growth rate
- Dependence on new product adoption (Colli-Pee Dx, OraQuick Ebola 2.0) for future growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398945 |
Track record
20 reports on OSUR
6 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +39.73% at T+60 after the Mar 13, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 10-Q/A Neutral 2/10 Entry $3.62 to $3.62 Now $3.60 −0.55% · 0.00% +0.36% vs SPY
- Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $3.33 to $3.56 Now $3.60 +8.11% ▲ +6.91% +5.59% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $3.53 to $3.33 Now $3.60 +1.98% ▼ −5.67% −5.30% vs SPY
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $3.46 to $3.53 Now $3.60 +4.20% ▲ +2.17% +1.87% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $3.94 to $3.46 Now $3.60 −8.63% ▼ −12.31% −11.83% vs SPY
- Sep 17, 20268w ago SC 13D Bullish 6/10 Entry $3.56 to $3.69 Now $3.60 +1.12% ▲ +3.65% +2.10% vs SPY
- Jul 23, 202616w ago Court Ruling Neutral 3/10 Entry $3.97 to $3.96 Now $3.60 −9.32% ▼ −0.25% −0.27% vs SPY
- Jun 12, 202622w ago Institutional Cluster Mixed 4/10 Entry $4.18 to $4.17 Now $3.60 −13.88% ▼ −0.24% −2.00% vs SPY
- Jun 3, 202623w ago 8-K Neutral 3/10 Entry $4.17 to $4.04 Now $3.60 −13.67% ▼ −3.12% −0.52% vs SPY
- May 6, 202627w ago 8-K Bearish 6/10 Entry $3.13 to $3.06 Now $3.60 −15.02% ▲ +2.24% +3.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers